ArticleCase reports in dermatology
A Case of Secukinumab in the Treatment of Psoriasis-Like Cutaneous Chronic Graft-versus-Host Disease.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic cutaneous graft-versus-host disease (cGVHD) represents a prevalent immune-mediated complication among patients with hematological malignancies following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Clinically, it commonly presents with lichenoid and sclerotic cutaneous lesions. However, reports in the literature on psoriatic manifestations associated with cGVHD remain scarce. Moreover, the evidence base regarding the use of biologic agents in the management of cGVHD is limited. Case Presentation: Herein, we present a case of psoriatic dermatitis in a patient with chronic cGVHD. The patient demonstrated a suboptimal response to conventional immunosuppressive therapies. Immunohistochemical analysis revealed positive expression of interleukin 17 (IL-17). Leveraging this finding, the patient was successfully treated with secukinumab, an anti-IL-17A monoclonal antibody. After 3 months of treatment, the cutaneous lesions had substantially resolved, with no reported adverse effects. Conclusion: Anti-IL-17A monoclonal antibody therapy may represent an alternative treatment modality for cGVHD patients presenting with psoriatic phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.